Interestingly, targeted ANC@RNP/crEGFR‐PLK1 therapy resulted in significant tumor growth reduction when compared to single gene editing counterparts (ANC@RNP/crEGFR or ANC@RNP/crPLK1; Figure 4b,c), indicating the synergistic role of dual EGFR and PLK1 inhibition in tumor progression. This evidence concerns the gene PLK1 and neoplasm.